Evolus, Inc. $EOLS Shares Purchased by Zimmer Partners LP

Zimmer Partners LP increased its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 21.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 505,000 shares of the company’s stock after acquiring an additional 88,500 shares during the quarter. Zimmer Partners LP owned about 0.78% of Evolus worth $6,075,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Evolus by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company’s stock valued at $347,000 after purchasing an additional 1,094 shares during the period. AlphaQuest LLC acquired a new position in Evolus in the first quarter valued at $39,000. Rhumbline Advisers increased its stake in Evolus by 4.1% in the first quarter. Rhumbline Advisers now owns 83,436 shares of the company’s stock valued at $1,004,000 after purchasing an additional 3,287 shares during the period. State of Wyoming increased its stake in Evolus by 988.1% in the first quarter. State of Wyoming now owns 3,754 shares of the company’s stock valued at $45,000 after purchasing an additional 3,409 shares during the period. Finally, ProShare Advisors LLC increased its stake in Evolus by 31.0% in the fourth quarter. ProShare Advisors LLC now owns 18,563 shares of the company’s stock valued at $205,000 after purchasing an additional 4,392 shares during the period. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EOLS. BTIG Research restated a “buy” rating and issued a $18.00 price objective on shares of Evolus in a research note on Monday. Needham & Company LLC restated a “hold” rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday, August 6th. HC Wainwright dropped their price target on shares of Evolus from $27.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Finally, Wall Street Zen lowered shares of Evolus from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Evolus presently has an average rating of “Moderate Buy” and an average price target of $21.25.

Insider Transactions at Evolus

In related news, Director Brady Stewart acquired 30,000 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were purchased at an average price of $6.82 per share, with a total value of $204,600.00. Following the completion of the acquisition, the director owned 88,629 shares in the company, valued at approximately $604,449.78. This represents a 51.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Moatazedi sold 111,323 shares of the business’s stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $10.05, for a total transaction of $1,118,796.15. Following the sale, the insider directly owned 381,509 shares in the company, valued at approximately $3,834,165.45. This represents a 22.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 133,627 shares of company stock worth $1,325,764 over the last ninety days. 6.10% of the stock is currently owned by company insiders.

Evolus Trading Down 0.7%

Shares of Evolus stock opened at $7.61 on Tuesday. Evolus, Inc. has a 52-week low of $5.71 and a 52-week high of $17.82. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00. The company’s 50-day simple moving average is $8.23 and its 200-day simple moving average is $10.08. The firm has a market cap of $492.21 million, a price-to-earnings ratio of -7.77 and a beta of 1.07.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.